Key Points
- COO Ross Moat sold 1,703 KNSA shares on April 9 at $46.69 (totaling $79,513.07) and had earlier sold 2,367 shares on April 6 at $48.58 (totaling $114,988.86), reducing his stake to 12,029 shares; the trades were disclosed to the SEC and the April 9 sale was executed under a pre-arranged Rule 10b5-1 plan.
- Kiniksa reported Q results with EPS of $0.17 (missing consensus $0.29) while revenue of $202.13M beat estimates and rose 65% year-over-year; the stock has a $3.62B market cap and a consensus analyst rating of Moderate Buy with an average price target of $55.29.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Ross Moat sold 1,703 shares of Kiniksa Pharmaceuticals International stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total value of $79,513.07. Following the sale, the chief operating officer directly owned 12,029 shares of the company's stock, valued at approximately $561,634.01. The trade was a 12.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ross Moat also recently made the following trade(s):
- On Monday, April 6th, Ross Moat sold 2,367 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $48.58, for a total value of $114,988.86.
Kiniksa Pharmaceuticals International Trading Up 0.5%
KNSA opened at $47.30 on Tuesday. The stock has a market cap of $3.62 billion, a price-to-earnings ratio of 63.92 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a 1 year low of $19.41 and a 1 year high of $50.03. The stock has a fifty day moving average price of $46.01 and a 200 day moving average price of $42.45.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.12). The firm had revenue of $202.13 million for the quarter, compared to analyst estimates of $200.86 million. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. Kiniksa Pharmaceuticals International's revenue for the quarter was up 65.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.12) EPS. As a group, sell-side analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Kiniksa Pharmaceuticals International
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. USA Financial Formulas acquired a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $32,000. Smartleaf Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $36,000. EverSource Wealth Advisors LLC lifted its holdings in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock worth $25,000 after purchasing an additional 532 shares during the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $41,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth approximately $41,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of analysts recently issued reports on KNSA shares. Weiss Ratings reissued a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Canaccord Genuity Group started coverage on Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They set a "buy" rating and a $62.00 price objective for the company. Wall Street Zen cut Kiniksa Pharmaceuticals International from a "buy" rating to a "hold" rating in a research report on Saturday, March 14th. Zacks Research raised Kiniksa Pharmaceuticals International from a "strong sell" rating to a "hold" rating in a research report on Wednesday, February 25th. Finally, Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 25th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of "Moderate Buy" and an average price target of $55.29.
View Our Latest Report on Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International Company Profile
(
Get Free Report)
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
